EmERGE validation study V3.0
Research type
Research Study
Full title
Validation study of mHealth technology in HIV to improve Empowerment and healthcare utilisation: Research and innovation to Generate Evidence for personalised care
IRAS ID
211169
Contact name
Jennifer Whetham
Contact email
Sponsor organisation
Fundació Clínic per la recerca biomédica
Duration of Study in the UK
2 years, 11 months, 30 days
Research summary
The EmERGE validation study will take place in five European sites to evaluate a redesigned clinical pathway for the care of patients living with stable HIV infection which includes the use of a mobile phone application or ‘app’.
Patients who are living with stable HIV infection at the five clinical sites (Brighton, Antwerp, Barcelona, Lisbon and Zagreb) will be invited to take part in the study. Patients who agree to take part in the study will be seen by their clinician once a year (rather than twice a year) with results from interim visits checked by a clinician and sent to them via an ‘app’ on their own mobile phone.
If a person becomes unwell or if the results are abnormal, patients will be reviewed in the clinic in the usual way. Some patients living with stable HIV attending the Brighton clinic are already seen once a year with interim results emailed to patients.
The 'app' or mobile Health (mHealth) platform is being developed as part of the wider EmERGE project, and its use will be evaluated by this validation study. The whole project is running over a period of five years – with patients being followed up within the validation study for between 12 and 35 months.
Patients taking part will be asked to complete questionnaires on empowerment, quality of life, adherence to medication, cost and patient experience at the beginning of the study and then annually. Additionally data will be collected on clinical outcomes and attendances to the clinic.
The total recruitment target is 3808 for all sites.
This project has received funding from the European Union’s Horizon 2020 research and innovation programme under Grant Agreement No. 643736.REC name
London - Brighton & Sussex Research Ethics Committee
REC reference
16/LO/2122
Date of REC Opinion
10 Jan 2017
REC opinion
Further Information Favourable Opinion